TY - JOUR
T1 - Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients with ST-Segment-Elevation Myocardial Infarction
T2 - Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines
AU - Pi, Yi
AU - Roe, Matthew T.
AU - Holmes, Dajuanicia N.
AU - Chiswell, Karen
AU - Garvey, J. Lee
AU - Fonarow, Gregg C.
AU - de Lemos, James A
AU - Garratt, Kirk N.
AU - Xian, Ying
N1 - Funding Information:
Dr Roe reports research funding from Eli Lilly, Sanofi-Aventis, Daiichi-Sanko, Janssen Pharmaceuticals, Ferring Pharmaceuticals, Astra Zeneca, American College of Cardiology, American Heart Association, and Familial Hypercholesterolemia Foundation; consulting or honoraria from PriMed, Astra Zeneca, Boehringer-Ingelheim, Merck, Amgen, Myokardia, Eli Lilly, Daiichi-Sankyo, and Elsevier Publishers. All conflicts of interest are listed at https:// www.dcri.org/about-us/conflict-of-interest. Dr Garvey reports research funding from Philips Healthcare and consulting or honoraria from Philips Healthcare. Dr Garratt reports research funding from Boston Scientific Corp; consulting or honoraria from Jarvik Heart, Astra Zeneca, Daiichi-Sankyo, and Boston Scientific Corp; and equity in LifeCuff, Inc and Guided Delivery Systems. The other authors report no conflicts.
Publisher Copyright:
© 2017 American Heart Association, Inc.
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Background - There are limited data on the utilization and outcomes of coronary artery bypass grafting (CABG) among ST-segment-elevation myocardial infarction (STEMI) patients in contemporary practice. Methods and Results - Using data from National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines between 2007 and 2014, we analyzed trends in CABG utilization and hospital-level variation in CABG rates. Patients undergoing CABG during the index admission were categorized by the most common scenarios: (1) CABG only as the primary reperfusion strategy; (2) CABG after primary percutaneous coronary intervention; and (3) CABG after fibrinolytic therapy. A total of 15 145 patients (6.3% of the STEMI population) underwent CABG during the index hospitalization, with a decrease in utilization from 8.3% in 2007 to 5.4% in 2014 (trend P value <0.001). The hospital-level use of CABG in STEMI varied widely from 0.5% to 36.2% (median, 5.3%; interquartile range [IQR], 3.5%-7.8%; P value <0.001). Of all patients undergoing CABG, 45.8% underwent CABG only, 38.7% had CABG after percutaneous coronary intervention, and 8.2% CABG after fibrinolytic therapy. The median time intervals from cardiac catheterization/percutaneous coronary intervention to CABG were 23.3 hours (IQR, 3.0-70.3 hours) in CABG only, 49.7 hours (IQR, 3.2-70.3 hours) in CABG after percutaneous coronary intervention, and 56.6 hours (IQR, 22.7-96.0 hours) in CABG after fibrinolytic therapy. The Acute Coronary Treatment and Intervention Outcomes Network mortality risk scores differed modestly (median, 33; IQR, 28-40 versus median, 32; IQR, 27-38) between CABG and non-CABG patients. Patients undergoing CABG had similar in-hospital mortality rate (5.4% versus 5.1%) as those not treated with CABG. Conclusions - CABG is performed infrequently in STEMI patients during the index hospitalization, with rates declining in contemporary US practice over time. There was marked hospital-level variation in the use of CABG, and CABG was typically performed within 1 to 3 days after angiography. Observed mortality rates appear low, suggesting that CABG might be safely performed in select STEMI patients in a timely fashion.
AB - Background - There are limited data on the utilization and outcomes of coronary artery bypass grafting (CABG) among ST-segment-elevation myocardial infarction (STEMI) patients in contemporary practice. Methods and Results - Using data from National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines between 2007 and 2014, we analyzed trends in CABG utilization and hospital-level variation in CABG rates. Patients undergoing CABG during the index admission were categorized by the most common scenarios: (1) CABG only as the primary reperfusion strategy; (2) CABG after primary percutaneous coronary intervention; and (3) CABG after fibrinolytic therapy. A total of 15 145 patients (6.3% of the STEMI population) underwent CABG during the index hospitalization, with a decrease in utilization from 8.3% in 2007 to 5.4% in 2014 (trend P value <0.001). The hospital-level use of CABG in STEMI varied widely from 0.5% to 36.2% (median, 5.3%; interquartile range [IQR], 3.5%-7.8%; P value <0.001). Of all patients undergoing CABG, 45.8% underwent CABG only, 38.7% had CABG after percutaneous coronary intervention, and 8.2% CABG after fibrinolytic therapy. The median time intervals from cardiac catheterization/percutaneous coronary intervention to CABG were 23.3 hours (IQR, 3.0-70.3 hours) in CABG only, 49.7 hours (IQR, 3.2-70.3 hours) in CABG after percutaneous coronary intervention, and 56.6 hours (IQR, 22.7-96.0 hours) in CABG after fibrinolytic therapy. The Acute Coronary Treatment and Intervention Outcomes Network mortality risk scores differed modestly (median, 33; IQR, 28-40 versus median, 32; IQR, 27-38) between CABG and non-CABG patients. Patients undergoing CABG had similar in-hospital mortality rate (5.4% versus 5.1%) as those not treated with CABG. Conclusions - CABG is performed infrequently in STEMI patients during the index hospitalization, with rates declining in contemporary US practice over time. There was marked hospital-level variation in the use of CABG, and CABG was typically performed within 1 to 3 days after angiography. Observed mortality rates appear low, suggesting that CABG might be safely performed in select STEMI patients in a timely fashion.
KW - coronary artery bypass
KW - hospital mortality
KW - hospitalization
KW - percutaneous coronary intervention
KW - thrombolytic therapy
UR - http://www.scopus.com/inward/record.url?scp=85028919540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028919540&partnerID=8YFLogxK
U2 - 10.1161/CIRCOUTCOMES.116.003490
DO - 10.1161/CIRCOUTCOMES.116.003490
M3 - Article
C2 - 28794118
AN - SCOPUS:85028919540
SN - 1941-7713
VL - 10
JO - Circulation: Cardiovascular Quality and Outcomes
JF - Circulation: Cardiovascular Quality and Outcomes
IS - 8
ER -